Mirabegron + Placebo
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Parkinsons Disease
Conditions
Parkinsons Disease
Trial Timeline
Mar 1, 2014 → Jul 1, 2018
NCT ID
NCT02092181About Mirabegron + Placebo
Mirabegron + Placebo is a approved stage product being developed by Astellas Pharma for Parkinsons Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02092181. Target conditions include Parkinsons Disease.
What happened to similar drugs?
1 of 2 similar drugs in Parkinsons Disease were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04641975 | Phase 3 | Terminated |
| NCT02787083 | Phase 3 | Terminated |
| NCT02216214 | Approved | Completed |
| NCT02086188 | Approved | Completed |
| NCT02092181 | Approved | Completed |
| NCT01284309 | Phase 1 | Completed |
| NCT00912964 | Phase 3 | Completed |
| NCT00662909 | Phase 3 | Completed |
| NCT00410514 | Phase 2 | Completed |
Competing Products
5 competing products in Parkinsons Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rivastigmine Patch 9.5 cm2 | Novartis | Approved | 43 |
| Prasinezumab + Placebo | Roche | Phase 2 | 39 |
| ALN-SNCA + Placebo | Regeneron Pharmaceuticals | Phase 1 | 36 |
| bemdaneprocel | Bayer | Phase 3 | 44 |
| High dose ANAVEX2-73 + Mid dose ANAVEX2-73 + Placebo oral capsule | Anavex Life Sciences | Phase 2 | 25 |